President and CEO of ONO PHARMA USA. "We encourage companies who are doing outstanding work in Ono's four focus areas – oncology, immunology, neurology, and specialty medicine – to apply.

April 26, 2025 /PRNewswire/ -- ONO PHARMA USA today announced partnerships ... The competition seeks proposals from startup companies in the oncology, immunology, neurology, and specialty areas.

Metastatic colorectal cancer (mCRC) continues to pose a clinical and commercial challenge, with low 5-year survival rates and limited durable respons ...

MUMBAI, India, May 12, 2025 /CNW/ -- Piramal Pharma Limited (NSE ... which are the platform for numerous oncology drugs. Sterile fill/finish represents the final stage of manufacturing for ...

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. When it comes to biotech ETFs, ...

In its 28th year, the annual MPW list recognizes 100 women leading major global companies. This year, 21 listees are at the ...

However its roots go a long way back: it was created through the merger of two top Swiss companies, Ciba-Geigy and Sandoz Laboratories, in what some say has been the "most successful pharma merger".

Discover why Genmab's antibody platforms, growing royalties, and late-stage pipeline make it a top biotech stock for ...

Boehringer Head of US Human Pharma Brian Hilberdink chats with Reuters' Patrick Wingrove at Reuters Pharma USA 2025 in Philadelphia ... in a decade; oncology; mental health, which goes way ...

DRL's management has guided for double-digit growth in FY26, with margins expected to remain similar to FY25 levels. Here's ...

We also hold significant stakes in BridgeBio Oncology Therapeutics and GondolaBio ... where we’re reliably finding something like 20% to 25% of patients actually harbor the gain of function ...